Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children
AMSTERDAM, March 26, 2026 /PRNewswire/ — Norgine B.V., a leading European specialty pharmaceutical company today announced that Swissmedic has granted marketing authorisation for PEDMARQSI® (sodium thiosulfate solution for infusion) indicated for the
